Table 1.

Clinical characteristics of MuSK-MG patients at the time of blood draw (N=31).

Patient NO.	Age(Yr)	Gender	Onset-age(Yr)	Disease duration(mo)	Race	ThymX	MGFA	MMT	Treatment (daily dose)
1	23	Female	22	13	B		2B	3	Pred 20mg
2	48	Female	36	150	W		I	1	MMF 2000mg
3	60	Female	45	186	B		2B	3	Pred 10mg+MMF2000mg
4	23	Female	10	154	B		2A	5	MMF 1500mg
5	46	Female	45	14	B		I	3	Pred 20mg
6	29	Female	20	109	B		0	0	None
7	67	Female	49	218	W		2A	3	MMF 2000mg
8	56	Female	42	161	W	Yes	2B	2	None
9	65	Female	53	139	W	Yes	1	3	Pred 1.25mg +MMF 2000mg
10	63	Female	51	146	W		3B	23	Pred 5mg +AZA 150mg
11	64	Female	30	402	W	Yes	2B	9	MMF 500mg
12	31	Female	26	58	B	Yes	3B	20	Plasma exchange
13	47	Female	34	157	B		2B	3	Pred 7.5mg + MMF 2000mg
14	23	Female	21	20	B		2A	2	Pred 30mg + MMF 2000mg
15	51	Male	43	94	B		1	1	AZA 75mg
16	26	Female	17	112	Mixed	Yes	2B	2	Pred 20mg + MMF 2500mg
17	58	Female	43	187	B	Yes	2B	5	MMF 2000mg
18	40	Female	34	78	B		2B	5	MMF 2000mg
19	31	Female	20	138	W		0	0	None
20	44	Female	29	185	B		2B	6	Pred 10mg
21	48	Female	32	184	B		2B	7	Pred 15mg
22	66	Female	48	215	W		2B	4	Pred 1mg
23	35	Female	33	28	B		3B	26	Mestinon 180mg + pred 30mg
24	45	Male	37	104	Unknown		2B	9	None
25	28	Female	4	288	W		2A	7	Pred 7.5mg + MMF 3000mg
26	48	Female	9	476	W		3B	31	Plasma exchange
27	56	Female	36	235	B		2A	21	None
28	58	Female	44	173	B		3B	27	Pred 20mg
29	53	Male	41	146	B	Yes	1	3	Pred 5mg
30	28	Female	27	16	W		2B	17	MMF 2000mg
31	25	Female	5	239	B	Yes	3A	4	Pred 3.8mg

Abbreviations: AZA = azathioprine; B = black; d = day; F = female; mg = milligrams; M= male; MGFA = Myasthenia Gravis Foundation of America; MM = minimal manifestations; MMF = mycophenolate mofetil; MMT = myasthenia gravis manual muscle testing score at time of blood draw; Mo = months; Pred = predinison; ThymX= thymectomy; W = white; Yr = years.